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The classical model of hematopoiesis predicts a
dichotomous lineage restriction of multipotent
hematopoietic progenitors (MPPs) into common
lymphoid progenitors (CLPs) and common myeloid
progenitors (CMPs). However, this idea has been
challenged by the identification of lymphoid progen-
itors retaining partial myeloid potential (e.g., LMPPs),
implying that granulocytes can arise within both the
classical lymphoid and the myeloid branches. Here,
we resolve this issue by using cell-surface CD133
expression to discriminate functional progenitor
populations. We show that eosinophilic and baso-
philic granulocytes as well as erythrocytes and
megakaryocytes derive from a common erythro-
myeloid progenitor (EMP), whereas neutrophilic
granulocytes arise independently within a lympho-
myeloid branch with long-term progenitor function.
These findings challenge the concept of a CMP and
restore dichotomy to the classical hematopoietic
model.
INTRODUCTION
Hematopoietic stem cells (HSCs) retain the dual capacities to
self-renew during the entire lifespan of an organism and to
generate all mature blood cell types via hierarchically organized
subsets of progenitors. In order to maintain homeostasis of the
mature blood system, strict regulation is required in processes
controlling self-renewal, lineage specification, and differentia-
tion. Characterization of themechanisms governing the develop-
ment of HSCs and their committed progeny is therefore a central
issue in stem cell research (Go¨rgens and Giebel, 2010).
An important prerequisite for uncovering such mechanisms is
a reliable model detailing the hierarchical interrelationship of
different hematopoietic progenitors and their mature offspring.
The prevailing model of the last 3 decades is the classical model
of hematopoiesis (Reya et al., 2001), based on dichotomous de-
cision processes through which multipotent HSCs create allCmature hematopoietic blood cell types. In detail, HSCs self-
renew and create multipotent hematopoietic progenitors
(MPPs) that have lost self-renewal potential. MPPs then generate
common myeloid progenitors (CMPs) and common lymphoid
progenitors (CLPs). In turn, the CMPs form progenitors of gran-
ulocytes and macrophages (GMPs) and of megakaryocytes and
erythrocytes (MEPs) (Akashi et al., 2000; Manz et al., 2002),
whereas CLPs give rise to progenitors of T and NK cells as
well as of B cells (Akashi et al., 2000; Kondo et al., 1997).
The recent identification of a number of murine and human
progenitors with nonclassical developmental potentials has
called this model into question (Giebel and Punzel, 2008;
Kawamoto et al., 2010). The identification of murine cells with
lymphoid developmental capacities that can also give rise to
granulocytes and macrophages but not to megakaryocytes
(MKs) or erythrocytes led to the definition of a new group of prim-
itive hematopoietic cells, termed lymphoid-primed multipotent
progenitors (LMPPs) (Adolfsson et al., 2005). A number of
groups, including our own, have also identified human pro-
genitors comprising full or partial lymphoid potential combined
with restricted myeloid capabilities (Ceredig et al., 2006;
Doulatov et al., 2010; Giebel et al., 2006; Haddad et al., 2004;
Reynaud et al., 2003). Progenitors present in the pool of
CD34+CD38CD90low/CD45RA+CD135+CD10+ cells are ca-
pable of generating all lymphocytes as well as macrophages
and dendritic cells and have been termedmultilymphoid progen-
itors (MLPs) (Doulatov et al., 2010). Human progenitors with
LMPP-like characteristics have been identified more recently
within the group of CD34+CD38CD45RA+CD10 cells (Goar-
don et al., 2011). The current view is therefore thatmacrophages,
dendritic cells, and granulocytes can derive from either CMPs or
LMPPs in both mouse and human.
This dual origin of myeloid cell types is not consistent with the
established concept of dichotomous lineage segregation and
raises questions concerning the mechanisms through which
multipotent progenitors progressively lose specific lineage po-
tentials. In our previous work on CD34+ cells, we revealed a cor-
relation between the occurrence of asymmetric cell divisions and
cell surface expression of the stem cell surrogate antigen
CD133/Prominin-1 (Beckmann et al., 2007). On the basis of
these observations, we hypothesized that CD133may be a help-
ful marker in resolving the segregation of lineages duringell Reports 3, 1539–1552, May 30, 2013 ª2013 The Authors 1539
Figure 1. Progenitors with Long-Term
Hematopoietic Potentials Are Highly
Concentrated within CD133+CD34+ Cell
Fractions
(A) Upper panels: CD133 expression on freshly
enriched, UCB-derived CD34+ cells. Lower
panels: relationship between CD133 and CD38
expression compared to isotype control on freshly
enriched CD34+ cells.
(B) CD133 and CD38 expression compared to
isotype controls on cultured (50–60 hr) CD34+
cells.
(C) CD133 and CD34 expression on cultured cells
before sorting and following sorting for CD34+,
CD34+CD133+, and CD34+CD133low.
(D) LTC-IC and NK-IC frequencies within sorted
fractions of culture-derived (50–60 hr) cells are
given as mean ± SD (*p < 0.05, **p < 0.01, ***p <
0.001).
(E) Quantification of human cell engraftment in
NOD/SCID mice, given as a percentage of viable
human CD45+ cells within the BM of NOD/SCID
mice 8 weeks postintravenous transplantation.
NOD/SCID mice were transplanted with 5 3 104
sorted CD133+CD34+ (CD133+) cells or
CD133lowCD34+ (CD133low) cells. Identical sym-
bols represent animals that received cells from the
same UCB samples.
(F) Multilineage analyses of a CD133+CD34+-
transplanted mouse. BM cells expressing human
CD45+ cells were further analyzed for their
expression of lymphoid and myeloid antigens.
(G) Analysis of human hematopoietic progenitor
markers within the BM of transplanted NOD/SCID
mice.
See also Figure S1.hematopoiesis. Because CD133 expression was largely ne-
glected in the studies that led to the identification of human
MLPs and LMPPs, we carried out a comprehensive analysis of
the developmental potential of CD34+ cells that expressed either
high CD133 or low/no CD133 on the cell surface. This has re-
vealed unexpected myeloid lineage relationships, leading to a
redefinition of the current model of human hematopoiesis.1540 Cell Reports 3, 1539–1552, May 30, 2013 ª2013 The AuthorsRESULTS
Hematopoietic Progenitors
Retaining Long-Term In Vitro and
In Vivo Potentials Reside in the
CD133+CD34+ Cell Fraction
Freshly enriched human hematopoietic
CD34+ (CD34+ [day 0]) cells can be
divided into CD133+ (CD133+ [day 0])
andCD133low/ (CD133low/ [day 0]) pop-
ulations (Beckmann et al., 2007; Giebel
et al., 2006; Yin et al., 1997). Here, we
confirmed that approximately 75% of
freshly isolated umbilical cord blood
(UCB) CD34+ cells and the majority of
the CD38low/ cells are in the CD133+
fraction (Figure 1A). Upon short-termcultivation (50–60 hr) in the presence of early-acting cytokines
(SCF, TPO, FLT3L), most CD34+ cells perform one cell division
in vitro (Beckmann et al., 2007). Themean level of CD133 expres-
sion increases over this period, whereas the population resolves
into approximately 60% CD133+ (CD133+ [day 3]) and 40%
CD133low (CD133low [day 3]) cells (Figure 1B). Simultaneously,
CD38 expression increased to reach similar levels in the
CD133+ (day 3) and CD133low (day 3) CD34+ populations,
although the highest CD38 expression was still found on
CD133low (day 3) cells (Figure 1B). To investigate the lineage re-
lationships between CD133+CD34+ and CD133lowCD34+ cells,
we compared the developmental capacities of each subpopula-
tion in a range of different functional readout systems.
For these analyses, we enriched CD133+ (day 3), CD133low
(day 3), and nonfractionated CD34+ (day 3) cells to more than
99.5% purity by flow cytometric cell sorting (Figure 1C). Initially,
we compared the long-termmyeloid and long-term lymphoid ca-
pacities of these cells in long-term culture-initiating cell (LTC-IC)
and natural killer cell-initiating cell (NK-IC) assays, respectively.
Both LTC-IC and NK-IC potentials were highly enriched in the
CD133+ (day 3) and strongly depleted from CD133low (day 3)
cell fractions (Figure 1D). This was also found to be the case
for freshly isolated cells (Figure S1A), showing that long-term
in vitro potential resides in CD133+CD34+ cells and is absent
from CD133lowCD34+ cells arising during short-term culture.
To compare the multilineage engraftment potential of CD133+
(day 3) and CD133low (day 3) cells, we injected aliquots of 50,000
sorted cells into the tail vein of sublethally irradiated NOD/SCID
mice. We found 15 of the 18 mice receiving CD133+ (day 3) cells
to harbor more than 0.1% human CD45+ cells in their bone
marrow (BM) 8 weeks posttransplantation (Figure 1E). All of
these mice showed multilineage engraftment in the BM (Fig-
ure 1F). Furthermore, the BMs of engrafted mice contained
both CD133+CD34+ and CD133low/CD34+ human progenitor
populations. Once again, the CD38lowCD34+ cells were predom-
inantly CD133+ (Figure 1G).
In contrast, only 5 out of 19 mice receiving CD133low (day 3)
cells harbored more than 0.1% BM cells reacting with the anti-
human CD45 antibody 8 weeks posttransplantation (Figure 1E).
These cells were negative for CD34, CD14, CD15, CD4, and
CD19 (data not shown). To test whether they might nonetheless
be descendants of progenitors that had disappeared by week 8,
we also looked for human cells 2 or 4 weeks after transplantation
with 50,000 or 150,000 CD133low (day 3) cells. No human cells
were detected in the BM (Figure S1B) or the spleens (data not
shown) of a total of 19 mice analyzed. We therefore conclude
that intravenously injected CD133low cells cannot engraft into
the BM of such animals and that the low-level staining observed
after 8 weeks was nonspecific. Thus, SCID-repopulating cells
(SRCs) reside exclusively within CD133+CD34+ cell fractions.
CFU-GM and CFU-G Reside Mainly within the
CD133+CD34+ Cell Fraction, whereas Most CFU-MIX
and BFU-E Are CD133lowCD34+
To compare the myeloid and erythroid potentials of the CD133+
and CD133low cell populations, we performed colony-forming
cell (CFC) assays discriminating progenitors retaining erythroid
(BFU-E), granulocyte (CFU-G), macrophage (CFU-M), both gran-
ulocyte and macrophage (CFU-GM), or mixed erythroid, granu-
locyte, and macrophage (CFU-MIX, also termed CFU-GEMM)
potential. CFU-MIXs are currently considered equivalent to
CMPs (Akashi et al., 2000).
We first analyzed the colony-forming potential of short-term
cultured CD34+ cells sorted into CD133+ (day 3) or CD133low
(day 3) populations. Although there was only a small differenceCin the colony-forming frequency (CD133+ [day 3] cells, 21% ±
4%; CD133low [day 3] cells, 27% ± 3%; n = 8; p = 0.0006), there
were major differences in the types of colonies generated. The
overwhelming majority of BFU-E and CFU-MIX colonies arose
from CD133low (day 3) cells, whereas CFU-GM and CFU-G
were enriched in the CD133+ (day 3) cell fraction (Figure 2A).
To confirm the observed differences, total colonies were har-
vested and analyzed by flow cytometry. In close agreement with
the CFC data, cells from CD133+ (day 3) colonies lacked the
erythroid cell surface antigens CD71 and Glycophorin A (Fig-
ure 2B). In contrast, a high proportion of cells from CD133low
(day 3) colonies expressed these markers (Figure 2B).
The observation that CFU-MIX colonies derive predominantly
from cultured CD133low (day 3) cells, whereas most CFU-GM
colonies arise fromCD133+ (day 3) fractions, was somewhat sur-
prising. Because progenitors with CFU-MIX potentials (shown
here to be CD133low) are assumed to be CMPs, whereas CFU-
GMs (shown here to be CD133+) are considered equivalent to
GMPs, our data imply that CD133+ GMPs do not derive from
CD133low CMPs, primitive CD133+ cells create CD133+ GMPs
via a transient CD133low CMP population, or the culture condi-
tions modulated the surface antigen expression of some of the
progenitors.
To exclude a potential impact of the 50–60 hr culture period on
the CD133 cell surface expression of CFCs, we next examined
the colony-formation potential of freshly isolated CD133+
(day 0) and CD133low/ (day 0) cells directly.
As shown in Figure 2C, the colony-forming capacity of freshly
isolated CD133low/ (day 0) cells was limited almost exclusively
to BFU-E, CFU-MIX, or CFU-G, comparable to the situation in
cultured cells. CD133+ (day 0) cells also resembled their cultured
counterparts, in having a high proportion of CFU-GM and
CFU-G. However, the frequencies of both BFU-E and CFU-
MIX were higher in the CD133+ (day 0) than in the CD133+ (day
3) population (Figure 2C). These data were again confirmed by
flow cytometry (Figure 2D). In summary, we conclude that
BFU-E and CFU-MIX activity is restricted largely to the
CD133low/ population and CFU-GM to the CD133+ population
both before and after short-term culture.
Neutrophils Are Derived from CD133+CD34+ Cells,
whereas Basophils and Eosinophils Arise from
CD133low/CD34+ Cells
The segregation of CFU-MIX and CFU-GM into CD133low/ and
CD133+ populations, respectively, questions the relationship be-
tween these progenitor cell types. To clarify this issue, we
decided to analyze the granulocytes in CD133low CFU-MIX and
CD133+ CFU-GM colonies in more detail. To this end, we
performed flow cytometric analyses of individually harvested
colonies (Figure S2A). CD15 and CD66b were used as pan-gran-
ulocyte markers and CD16 and CD49d to discriminate neutro-
phils from other granulocytes (Bochner et al., 1991; Hartnell
et al., 1990). We detected CD15+CD66b+ granulocytes in all
CD133+ (day 3) CFU-GM (n = 12) and CD133low (day 3) CFU-
MIX colonies (n = 12) analyzed. Importantly, CD16+CD49d
(neutrophil) cells were found in all CD133+ (day 3) CFU-GM col-
onies but in none of the CD133low CFU-Mix colonies (Figure 2E).
Next, we performed a comparable analysis of colonies derivedell Reports 3, 1539–1552, May 30, 2013 ª2013 The Authors 1541
Figure 2. CD133+CD34+ and CD133low
CD34+ Cell Fractions Contain Different
Qualities of Myeloid/Erythroid Progenitors
(A) Myeloid/erythroid colony formation of culture-
derived CD133+CD34+ and CD133lowCD34+ cells.
Colony numbers are indicated per 100 seeded
cells (mean ± SD; **p < 0.01, ***p < 0.001).
(B) Flow cytometric analyses of dissociated colony
cells. Erythroid cells (E) were discriminated from
nonerythroid cells (NE) by anti-CD45 and anti-GPA
staining. Erythroid progenitors were identified as
CD71+GPAlow cells.
(C) Myeloid/erythroid colony formation from
freshly isolated CD133+CD34+ and CD133low
CD34+ cells.
(D) Analyses of the cell surface phenotype of col-
ony-derived cells originating from freshly isolated
CD34+ cells.
(E) Analyses of the cell surface phenotype of cells
derived from CD133+ (day 3) CFU-GM and
CD133low (day 3) CFU-MIX colonies. A total of 12
individual colonies of each type was harvested
from four different UCBs, stained, and analyzed by
flow cytometry. Granulocytes were identified as
CD45+ cells (CD45+), expressing the cell surface
antigens CD15 and CD66b (GRAN). CD16 and
CD49d expression on granulocytes was analyzed
separately.
(F) For analyses of day 0 colony-derived cells, 12
individual CD133+ (day 0) CFU-G colonies and 19
CD133+ (day 0) CFU-MIX colonies were harvested
from four different UCB samples and stained. Of
the 19 CFU-MIX colonies tested, 4 contained
CD16+/CD49d granulocytes.
See also Figure S2.from freshly isolated fractions. CD16+CD49d neutrophils were
detected in all CFU-G (n = 12) and in 4 out of 19 CFU-MIX col-
onies derived from the CD133+ (day 0) population (Figure 2F).
In contrast, none of CFU-G (n = 9) or CFU-MIX colonies (n =
12) arising from CD133low/ (day 0) cells contained such cells
(data not shown). These results imply that neutrophils derive
exclusively fromCD133+CD34+ cells. To confirm this, we studied
the morphology of colony-derived cells in cytospin preparations.
Consistent with the results described above, CD133+ (day 3)
CFU-GM colonies and CD133+ (day 0) CFU-G colonies con-
tained exclusively neutrophilic granulocytes, whereas CD133low
(day 3) CFU-MIX colonies contained eosinophils, basophils,
macrophages, and a few MKs, but no neutrophils. These col-
onies also contained a small number of granulocytes with both
eosinophilic and basophilic granules (Figures 3A and 3F). Hybrid1542 Cell Reports 3, 1539–1552, May 30, 2013 ª2013 The Authorseosinophilic/basophilic granulocytes of
this description have been detected pre-
viously in BM and peripheral blood of pa-
tients with myeloid leukemia and from
UCB (Boyce et al., 1995; Poch et al.,
1973; Weil and Hrisinko, 1987) and have
been proposed to represent a common
eosinophil-basophil progenitor (Denburg
et al., 1985). Notably, many more of these
mixed eosinophilic-basophilic cells weredetected in CFU-G and CFU-MIX colonies derived from
CD133low/ (day 0) cells (Figures 3B and 3F).
Within the comparatively low number of CFU-MIXs arising
from CD133+ (day 0) cells, we detected very few mature granu-
locytes, most of the cells having an immature appearance (Fig-
ure 3B). Because the 2-week CFC assay might be insufficient
to permit development of mature granulocytes from the earliest
CFC, we further investigated the granulocytic potential in a re-
plating assay.
To this end, cellswereharvested fromsingleCD133+ (day0)and
CD133low/ (day 0)-derived CFU-MIX colonies and replated into
secondary colony assays. Consistent with the persistence of pro-
genitors noted above, only CFU-MIX from the CD133+ (day 0)
fraction formed secondary colonies (CD133+ CFU-MIX, n = 16;
CD133low/ CFU-MIX, n = 10), most of which were myeloid
(Figure 3C). Of eight colonies analyzed by flow cytometry, all con-
tained CD16+ granulocytes (Figure 3D). Strikingly, all 16 second-
ary colonies analyzed morphologically contained neutro-
phils, eosinophils, and basophils as well as macrophages and
erythroid cells (Figures 3E and 3F). Notably, the frequency of
immature cells was far lower in the secondary than in the primary
colonies. A proportion of primary BFU-E colonies contains non-
recognized myeloid progenitor cells with potentials to form sec-
ondary colonies (Metcalf et al., 1979). To test for the presence of
misclassified BFU-E colonies, we also replated BFU-E colonies.
None of the CD133low/ (day 0) BFU-Es formed secondary col-
onies (n = 10); in contrast, ten out of ten replated CD133+ (day 0)
BFU-E colonies revealed the same potential as the replated
CD133+ (day 0) CFU-MIX colonies (data not shown), demon-
strating that CD133+ BFU-Es were in fact CFU-MIX colonies.
These morphological observations were confirmed at the mo-
lecular level by expression analysis of granulocyte genes specific
for neutrophils (myeloperoxidase, MPO), eosinophils (eosinophil
peroxidase, EPX), and basophils (histidine decarboxylase, HDC).
Consistent with the findings described above, CD133+ (day 3)-
derived CFU-GM colonies contained MPO, but no EPX or HDC
transcripts, whereas CFU-MIX colonies from the CD133low
(day 3) fraction contained EPX and HDC transcripts in the
absence of MPO (Figure 3G). Similarly, CFU-G colonies from
the freshly isolated CD133+ (day 0) fraction exclusively ex-
pressed MPO, whereas those from the CD133low/ (day 0) frac-
tion expressed only EPX/HDC transcripts (Figure 3H). As was the
case with the CD133low (day 3) fraction, CD133low (day 0) cells
generated CFU-MIX colonies containing EPX and HDC tran-
scripts in the absence ofMPO (Figure 3H). The CFU-MIX arising
from the CD133+ (day 0) fraction had low-level expression of EPX
andHDC, but none ofMPO (Figure 3H). However, the expression
of MPO, EPX, and HDC was confirmed in secondary colonies
(data not shown), consistent with the presence of immature pro-
genitors for each lineage in the CD133 (day 0) CFU-MIX colonies.
In summary, our results indicate that neutrophils arise exclu-
sively from CD133+CD34+ cells, whereas basophils and eosino-
phils derive mainly from CD133low/CD34+ cells. CD133+CD34+
cells with CFU-MIX potential are the most primitive cells that can
be detected in the CFC assay and were the only progenitors re-
taining the capability to generate neutrophils aswell as basophils
and eosinophils.
Cultured CD133+CD34+ Cell Fractions Gradually Lose
CFU-MIX, Erythroid, and MK Potentials
The results described above make it highly unlikely that
CD133low/ CFU-MIXs are hierarchical ancestors of the
CD133+CD34+ CFU-GMs. Indeed, CD34+CD133low/ (day 0)
cells sorted into short-term culture remained CD133low,
whereas sorted CD34+CD133+(day 0) cells under the same con-
ditions generated both CD133+ and CD133low cells (Figures 4A
and S3A).
Progenies of the CD133low/ (day 0) cells were sorted again on
day 3 as CD133low/ (day 3;) cells and those of CD133+
(day 0) cells as CD133low (day 3; +) or CD133+ (day 3; ++) cells,
respectively (Figures 4A and S3A). Again, defined cell numbers
were seeded into functional assays, whereas the remaining cells
were cultured for another 3 days (day 3 to day 6; Figure 4A). TheCtendency of CD133+CD34+ cells to generate CD133lowCD34+
cells decreased over time, coincident with an increased
and presumably direct production of CD133CD34 cells
(Figure 4A).
In agreement with the CFC data described above, CD133low/
(day 0) cell fractions lacked CFU-GM potential but contained a
high frequency of progenitors with BFU-E or CFU-MIX activity
compared to the CD133+ (day 0) cell fractions.
The data obtained with CD133+ (day 0) cells and their day 3
descendants imply that the erythroid potentials initially found
within the CD133+ (day 0) cell fraction segregate into the
CD133low (day 3) cell fraction during short-term culture. Accord-
ingly, cells with erythroid potentials are progressively depleted
from the CD133+CD34+ cell fraction (Figure 4B). In contrast,
most cells with CFU-GM potential retain their CD133+CD34+
phenotype throughout the culture period (Figure 4B).
To verify the CFC data, we studied the potential of
CD133+CD34+ and CD133low/CD34+ cells to form erythroid
cells in a liquid culture system commonly used to generate
mature erythrocytes (Dorn et al., 2008). Consistent with the re-
sults of the CFC assays, erythroid potential was highest in
CD133low/CD34+ (day 0) cells and decreased markedly by
day 3 of culture. Furthermore, most of the erythroid potential of
the CD133+ (day 0) cells was retained at day 3 within the arising
CD133low (day 3) progeny. The potential to form erythroid cells in
the liquid culture system had been lost almost completely by
day 6 of culture (Figures 4C and S3B).
Because erythrocytes and MKs are generally accepted to
derive from a common MK/erythrocyte progenitor (MEP) (Akashi
et al., 2000), we adapted aMK differentiation assay (Hogge et al.,
1997) to investigate whether CD133+CD34+ cells also lose their
MK potential with increasing cell culture periods. Progenitors
with MK potential were initially found in both the CD133+
(day 0) and the CD133low/ (day 0) fractions, and the number of
MKs obtained was reduced in both cell fractions during culture
(Figures 4D and S3C). As with the erythroid potential, the MK
potential of the CD133+ population appeared to segregate into
the newly arising CD133lowCD34+ cell fractions during culture
(Figure 4D).
Because erythroid, MK, and eosinophil development depends
on the activity of the transcription factors Gata-1 andGata-2 (Hir-
asawa et al., 2002; Iwasaki et al., 2003; Kitajima et al., 2006), we
next studied their expression in the different subpopulations. In
agreement with the results of the functional readouts, Gata-1
and Gata-2 were expressed at high levels in CD133low/ (day 0)
and CD133low (day 3; +) cells, at an intermediate level in
CD133+ (day 0) cells, and at a low level in CD133+ (day 3; ++)
cells (Figure 4E).
In summary, progenitors with CFU-MIX, erythroid, or MK po-
tentials were gradually lost from CD133+CD34+ cell fractions,
most likely via segregation into CD133lowCD34+ cell fractions.
CD133+CD34+ Cells that Had Been Cultured for 9 Days
Displayed NSG-Repopulating Cell Activities but Lacked
In-Vivo-Inducible Erythroid Potential
To exclude the possibility that the cultured CD133+CD34+ pop-
ulations retain latent erythroid/MK potential that could not be re-
cruited in the in vitro assays, we compared their in vivo potentialell Reports 3, 1539–1552, May 30, 2013 ª2013 The Authors 1543
Figure 3. CD133+CD34+ and CD133lowCD34+ Generate Different Granulocyte Types
(A) Modified Wright’s staining of colonies derived from cultured cells. Neutrophils (Neutro) were detected exclusively in CD133+CD34+ CFU-GM colonies. In
contrast, erythroid cells (Ery), MK, eosinophils (Eos), and basophils (Bas) as well as eosinophil/basophil hybrid cells (Hybrid) were found exclusively in
CD133lowCD34+ CFU-MIX colonies. Macrophages (Mac) were identified in both colony types. Scale bars, 10 mm (n = 3 UCBs).
(B) Modified Wright’s staining of colonies derived from fresh cells. Day 0 CD133+CD34+ CFU-G colonies contained neutrophilic cells, ranging from immature to
band neutrophils. CD133+CD34+ CFU-MIX colonies mainly contained immature cells, erythroid cells, and some macrophages. CD133lowCD34+ CFU-G colonies
contained eosinophils, basophils, and a large proportion of leukocytes containing both eosinophil and basophil granules, but no neutrophils. CD133lowCD34+
CFU-MIX colonies included macrophages, erythroid cells, eosinophils, basophils, hybrid cells, a small proportion of MKs, and only few immature cells, but never
neutrophils. Scale bars, 10 mm.
(C) Day 0 CD133+CD34+ and CD133lowCD34+ CFU-MIX colonies were harvested after 2 weeks (16 and 10 colonies, respectively, originating from two different
UCBs) and replated in CFC assays. Secondary CFC potential was documented after 12 days. Cells of CD133+CD34+ CFU-MIX colonies revealed pronounced
myeloid colony-formation potential (CFU-G/-M/-GM) with rare erythroid or CFU-MIX colonies. In contrast, cells from CD133lowCD34+ CFU-MIX colonies had no
secondary colony-formation potential. Scale bars, 200 mm.
(legend continued on next page)
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Figure 4. CFU-MIX, Erythroid, and MK
Potentials Are Gradually Lost from
CD34+CD133+ Cell Fractions upon Cultiva-
tion
(A) Sorting and cultivation strategy to analyze
the erythro-myeloid lineage potential of
CD133+CD34+ and CD133lowCD34+ sub-
populations. Freshly enriched CD34+ cells were
initially purified at day 0 as CD133+CD34+ (+) and
CD133low/CD34+ () cells. The descendants of
these cells were sorted again on day 3 as ‘++, +,
or cells, and their descendants in turn on day 6
as +++, ++-, +, or ’ cells. At each time
point, aliquots of each sorted cell fraction were
analyzed in CFC assays (B), erythroid differentia-
tion assays (C), and MK differentiation assays (D)
with the remainder being returned to culture in the
presence of SCF, TPO, and FLT3L.
(B) Analyses of the erythro-myeloid colony-forma-
tionpotentialofCD133+CD34+andCD133lowCD34+
cells (n = 4). Colony numbers are indicated per 100
originally seeded cells (mean ± SD).
(C) Analyses of the erythroid differentiation
potential of purified CD133+CD34+ and
CD133lowCD34+ cells in erythroid differentiation
assays.
(D) Analyses of the MK differentiation potential of
purified CD133+CD34+ and CD133lowCD34+ cells
in MK differentiation assays.
Numbers of erythroid (C) or MKs (D) generated
were normalized to 1,000 originally seeded cells
and are given as mean ± SD. Numbers above bars
indicate numbers of independently performed
experiments. Brackets indicate comparison ana-
lyses with p values.
(E) Quantitative PCR analysis of Gata-1 and Gata-
2 expression, normalized to their expression in
CD34+CD133+ (day 0) cells (n = 3; mean ± SEM).
See also Figure S3.in a xenotransplant NSG mouse model. To determine the multi-
lineage potential after 3 days of culture, 150,000 sorted CD133+
(day 3) cells were transplanted intravenously into sublethally irra-
diated mice; for the same test after 9 days of culture, approxi-(D) The pool of secondary colony cells derived from day 0 CD133+CD34+ CFU-MIX colonies was analyze
contained CD16+ granulocytes.
(E) All pools of secondary day 0 CD133+CD34+ CFU-MIX colony cells (n = 16) contained mature, segmen
macrophages, erythroid cells, and few MKs. Scale bars, 10 mm.
(F) Summary of the lineage analyses of day 0 colonies based on their histology.
(G) RT-PCR analyses of neutrophil-specific MPO, eosinophil-specific EPX, and basophil-specific HDC expre
three independent experiments, RNA was extracted from pools of five individually harvested CD133+CD34+
(H) RT-PCR analyses ofMPO, EPX, andHDC in day 0 colony-derived cells, derived either fromCD133+CD34+
three independent experiments for each colony type, RNA was extracted from pools of five individually harv
Cell Reports 3, 1539–155mately 2 3 106 sorted CD133+CD34+
(day 9) cells were transplanted (Fig-
ure 5A). In both settings, we observed
engraftment levels ranging from 0.5% to
9% human cells within the murine BM
8 weeks posttransplantation. All of these
mice showed multilineage engraftment
(Figure S4A) and contained hematopoiet-ic CD34+ cells (Figure 5A). Interestingly, mice engrafted with
CD133+ (day 3) cells (n = 15) contained higher proportions of
CD133low/CD34+ cells within their CD34+ cell fraction than did
those transplanted with CD133+ (day 9) cells (n = 6) (Figure 5A).d flow cytometrically. Eight out of eight fractions
ted neutrophils as well as eosinophils, basophils,
ssion in day 3 colony-derived cells. In each of the
CFU-GM or CD133lowCD34+ CFU-MIX colonies.
or CD133lowCD34+ CFU-G or CFU-MIX colonies. In
ested colonies.
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Figure 5. Comparison of the In Vivo Differentiation Potential of Day 3 CD133+CD34+ and Day 9 CD133+CD34+ Cells
(A) Purification strategy for CD133+CD34+ cells after 3 or 9 days of culture. A total of 150,000 sorted day 3 cells or 23 106 sorted day 9 CD133+CD34+ cells were
transplanted into sublethally irradiated NSG mice. BM of transplanted mice was harvested 8 weeks posttransplantation and analyzed for multilineage
engraftment (Figure S4A) as well as for the content of CD133+CD34+ and CD133lowCD34+ cells within the human CD34+ cell fraction, given as mean ± SD.
(B) CD133+CD34+ (CD133+) and CD133lowCD34+ (CD133low) cells within the mouse BM were sorted by flow cytometry (Figure S4B) and transferred into CFC
assays. The average colony-forming activity of these cells is given for each colony type or in total per 100 sort-purified CD133+CD34+ or CD133lowCD34+ cells as
mean ± SD. Brackets indicate comparison analyses with p values: *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S4.To test whether the in vivo environment of NSGmice can restore
the capability of CD133+ (day 9) cells to differentiate along
the MEP lineage, we sorted human CD133+CD34+ and
CD133low/CD34+ cells from murine BM (Figure S4B) and trans-
ferred discrete numbers into CFC assays. Although CD34+ de-
scendants of the CD133+ (day 3) cells clearly retained BFU-E
andCFU-MIX potential (mostly in theCD133low/CD34+ cell frac-
tion), the CD34+ descendants of CD133+ (day 9) cells showed
negligible BFU-E or CFU-MIX activity (Figure 5B). This shows
that the CD133+CD34+ cell fractions do indeed lose their CFU-
MIX and erythroid potentials over time, while retaining their abil-
ity to engraft and initiate multilineage development in NSG mice.1546 Cell Reports 3, 1539–1552, May 30, 2013 ª2013 The AuthorsIn this context, it is tempting to speculate that the engrafting
CD133+ (day 9) cells might correspond to progenitors with
LMPP potentials.
MPPs, LMPPs,MLPs, andGMPsReside inCD133+CD34+
Cell Fractions
As described above, it is possible that CD133+ cells that engraft
without erythroid potential are related to progenitors previously
described to retain lymphoid and partial myeloid potential. We
therefore analyzed the expression of CD133 in cell populations
of freshly isolated CD34+ cells that were shown to be enriched
for MPPs, LMPPs, MLPs, GMPs, CMPs, and MEPs (Doulatov
Figure 6. Expression of CD133 on Defined Progenitor Subpopulations
(A) Expression of CD133 on immunophenotypically defined progenitor populations of freshly isolated UCB CD34+ cells using a CD45RA/CD135-based gating
strategy similar to Doulatov et al. (2010).
(B) Expression of CD135 on defined CD34+ progenitors using a CD45RA/CD133-based gating strategy on the same data file presented in (A).
See also Figure S5.et al., 2010; Goardon et al., 2011; Manz et al., 2002). We first
confirmed that CD133+ (day 0) cells are negative for lineage
markers (Figure S5A). We then found that the MPP- and
LMPP-containing fractions enriched on the basis of differential
CD34, CD38, CD135, and CD45RA expression also express
CD133, whereas the nonlymphoid MEP fraction lacks CD133
expression. Interestingly, although the majority of CD34+ cells
express equivalent amounts of CD135 and CD133 on their
surface (Figure S5B), the CMP and GMP fractions defined on
the basis of CD135 expression comprise both CD133+ and
CD133low/ subpopulations (Figure 6A). Using an alternative
gating strategy, in which CD34+CD38+ and CD34+CD38low cells
are first separated on the basis of CD133 and CD45RA expres-
sion and then analyzed for CD135 expression, more homoge-
neous populations can be identified (Figure 6B).
This led us to propose that CD133 expression may provide
a basis for more accurate discrimination of lympho-myeloid
potentials, with MPPs being CD133+CD34+CD38lowCD45RA,
LMPPs CD133+CD34+CD38lowCD45RA+CD10, MLPs CD133+
CD34+CD38lowCD45RA+CD10+, and GMPs CD133+CD34+CCD38+CD45RA+CD10CD7. We therefore compared the
developmental potential of these sorted fractions (Figure 7A) in
both an enhanced MS5 assay (Doulatov et al., 2010) and the
CFC assay.
The MS5 assay employed reveals the potential of individually
deposited cells to generate myeloid (CD14+ monocytes/macro-
phages and/or CD15+ granulocytes) and/or lymphoid cells
(CD19+ B cells and/or CD56+ NK cells) (Figure 7B). We did
indeed observe a remarkably high proportion of lympho-myeloid
progenitors within the MPP, LMPP, and MLP fractions defined
on the basis of CD133 expression, whereas the large majority
of progenitors in the GMP fraction gave rise to myeloid cells
only (Figure 7C; Table S1). Monocytic cells were generated
from all fractions and granulocytes from all but the MLP fraction
(Figure S6A; Table S1). In agreement with Doulatov et al. (2010),
we detected cells within the GMP fraction that generated ex-
clusively lymphoid progeny. Cytospin analyses confirmed the
presence of neutrophils in MPP, GMP, and LMPP derivatives.
However, we did not detect eosinophils or basophils in any of
the cytospins (data not shown).ell Reports 3, 1539–1552, May 30, 2013 ª2013 The Authors 1547
Figure 7. Cell Fate Analyses of Individual Progenitors Define a Revised Model of Early Hematopoiesis
(A) Sorting strategy to enrich for MPPs, LMPPs, MLPs, and GMPs.
(B) Representative examples of the flow cytometric characterization of the CD45+ progeny fraction of individually deposited progenitors raised for 4 weeks in the
MS5 assay (Doulatov et al., 2010).
(C) Quantification of the myeloid, lymphoid, and lympho-myeloid lineage output of individually deposited cells of theMPP-, LMPP-, MLP-, and GMP-enriched cell
fractions (mean ± SD).
(D) CFC assay of MPP-, LMPP-, MLP-, and GMP-enriched cell fractions (mean ± SD).
(E) Wright’s staining of cells isolated from CFC assays indicates the presence of basophils, eosinophils (asterisk), neutrophils (arrowhead), and macrophages
(arrow) in MPP-derived colonies. In contrast, no basophils and eosinophils were detected in LMPP- and GMP-derived colonies (scale bars, 10 mm). Myeloid cell
types detected within bulk colonies are given.
(legend continued on next page)
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The CFC assays showed that CFU-MIX potentials reside spe-
cifically within MPP fractions. The MLP fraction hardly revealed
any CFC potential, and cells of both the LMPP and GMP frac-
tions formed high frequencies of GM, G, and M colonies (Fig-
ure 7D). In cytospins, neutrophils were detected in colonies of
MPP, LMPP, andGMP fractions; in contrast, eosinophils and ba-
sophils were exclusively found in MPP-derived colonies (Fig-
ure 7E). Thus, the results of the MS5 and CFC assays imply
that the CD133+CD34+CD38lowCD45RA MPP fraction is highly
enriched formultipotent cells, and cells of the other CD133+ frac-
tions have indeed lost erythro-myeloid potentials.
Finally, we examined cells of the CD133+ subpopulations and
CD133lowCD34+ cells for expression of the lineage-associated
transcription factors Gata-1, Gata-2, C/EBPa, and PU-1 as well
asNotch1, which has recently been found to be highly expressed
in LMPP-like cells (Goardon et al., 2011). The highest levels of
Gata expression were found in CD133lowCD34+CD38+CD45RA
cells (Figure 7F). Within the CD133+ compartment, Gata expres-
sionwas restricted largely to theMPP fraction, significantly lower
in the LMPP, and barely detectable in the MLP and GMP frac-
tions. In contrast, the highest levels of C/EBPa were detected
in LMPP and GMP and PU.1 in MLP fractions. Consistent with
the report of Goardon et al. (2011), we foundNotch-1 expression
to be highest within the LMPP fraction.
DISCUSSION
We report here a detailed analysis of the developmental potential
of freshly isolated and short-term cultured humanCD133+CD34+
andCD133low/CD34+ hematopoietic progenitors. We show that
(1) basophils and eosinophils derive from a common progenitor
(eosinophil/basophil progenitor [EoBP]); (2) EoBPs derive in
turn from CD133low/CD34+ erythro-myeloid progenitors
(EMPs) that have no neutrophil potential but do give rise to eryth-
rocytes and MKs; (3) EMPs are produced from CD34+CD133+
MPPs, which also appear to be the source of LMPPs retaining
neutrophil and macrophage but no eosinophil or basophil poten-
tial; and (4) at least two different qualities of CD133+CD34+ cells
can engraft into NSG mice as multipotent progenitors either re-
taining or lacking erythro-myeloid potential.
The classical model of hematopoiesis predicts that the
lymphoid and myeloid potentials of multipotent progenitors
segregate in a dichotomous manner into CLPs and CMPs,
respectively (Figure 7G) (Akashi et al., 2000; Kondo et al.,
1997; Manz et al., 2002). However, starting with the discovery
of LMPPs in mouse (Adolfsson et al., 2005), there has been a se-
ries of observations that are inconsistent with an exclusive
segregation of lymphoid and myeloid potentials into CLPs and
CMPs (Bell and Bhandoola, 2008; Giebel et al., 2006; Goardon
et al., 2011; Wada et al., 2008). To accommodate this, Adolfsson
et al. (2005) proposed the composite model (Figure 7G) in which
MPPs create LMPPs and CMPs, both of which have the potential(F) Quantitative PCR analysis of Gata-1, Gata-2, C/EBPa, PU.1, and Notch1 ex
in erythro-myeloid CD133lowCD34+CD38+CD45RA (CD133lowCD45RA) cells
mean ± SEM).
(G) Graphical overview of the classical (Reya et al., 2001), composite (Adolfsson
See also Figure S6 and Table S1.
Cto generate GMPs. One striking finding of our study is that
although both progenitors can create granulocytes, human
LMPPs generate only neutrophils via GMPs, whereas
CD133low/ cells with CFU-MIX potential (presumed equivalent
to CMPs) generate only eosinophils and basophils, which appear
to develop via a common EoBP. The existence of common
EoBPs has been proposed previously by Boyce et al. (1995),
Denburg et al. (1985), and Leary andOgawa (1984), and ‘‘hybrid’’
granulocytes with eosinophil and basophil granules have been
described in patients with leukemia by Mlynek and Leder
(1986), Poch et al. (1973), andWeil and Hrisinko (1987). In our an-
alyses, we did not observe any cell that exclusively showed the
potential to form all myeloid cell types. TheCD133+CFU-MIX ap-
peared as multipotent cells retaining lymphoid potential, and the
CD133low CFU-MIX lacked the potential to create neutrophils.
Thus, our data challenge the existence of true CMPs, suggesting
that cells previously identified as CMPs actually correspond to
an EMP cell lacking the GMP potential. A number of historical
findings are compatible with the existence of EMPs of this
description: The leukemic cell line UT-7 was found to contain
basophilic, eosinophilic, MK, and erythroid potentials only (Her-
mine et al., 1992), whereas the group of Ogawa identified er-
ythro-eosinophil colonies that in replating experiments only
gave rise to eosinophilic and erythroid colonies (Nakahata
et al., 1982). More recently, the group of Akashi reported that hu-
man eosinophil progenitors derived neither from GMPs nor from
MEPs (Mori et al., 2009). Although we have not considered mast
cells in our study, a progenitor combining basophil and mast cell
potential has been reported in mice (Arinobu et al., 2005). It will
be interesting to determine whether mast cells, which like eosin-
ophils and basophils, develop in a Gata-1-dependent manner
(Harigae et al., 1998; Iwasaki et al., 2006), also arise from EoBPs.
Both GMPs and LMPPs generate similar frequencies of CFU-
GM in a CFC assay that excludes lymphoid development. How-
ever, the stromal MS5 assay that supports both lymphoid and
myeloid development revealed a clear difference in potential,
with a high proportion of LMPPs generating both lymphoid and
myeloid cells. Phenotypically, GMPs are highly enriched within
the CD133+CD34+CD38+CD45RA+ fraction and LMPPs in the
CD133+CD34+CD38lowCD45RA+ fraction. Further subdivision
on the basis of CD10 expression yields a CD10+myelo-lymphoid
fraction that lacks both granulocyte potential, and CFC activity
and corresponds to the MLPs recently described by Doulatov
et al. (2010), and a CD10 LMPP fraction (Goardon et al.,
2011; Kohn et al., 2012). Based on their potentials, we assume
that LMPPs generate GMPs and MLPs, both of which retain
monocytic/macrophage potential. Because we also detected
monocytic cells in CD133low CFU-MIX colonies, our data support
the myeloid-based model of hematopoiesis. This proposes that
the evolutionary prototype of all blood cells was a macrophage-
like cell that evolved to a variety of specialized types (e.g., T and
B cells, erythroid cells) and that remnants of the prototypepression in MPP-, LMPP-, MLP-, and GMP-enriched cell fractions as well as
, normalized to their expression within the MPP-enriched fraction (n = 3;
et al., 2005), and revised model of hematopoiesis proposed here.
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remain as a default in most specialized lineages (Kawamoto and
Katsura, 2009).
In summary, and taking into account our previous findings
that the generation of CD133low/CD34+ cells from the
CD133+CD34+ fraction correlates with asymmetric cell division
events (Beckmann et al., 2007; Giebel et al., 2006), we propose
that HSCs give rise to MPPs, which in turn create LMPPs and
EMPs by a process that presumably involves asymmetric cell di-
vision. LMPPs lacking erythroid potential nonetheless retain the
capacity to reconstitute immune-compromisedmice and to form
LTC-IC and NK-IC colonies (Giebel et al., 2006). In contrast,
EMPs inherit the MK/erythroid potential and the potential to
form basophils and eosinophils (Figure 7G).
EXPERIMENTAL PROCEDURES
Cell Source and Preparation
Human UCB was obtained from unrelated donors after informed consent ac-
cording to the Declaration of Helsinki. Mononuclear cells (MNCs) were isolated
from individual sources by Ficoll (Biocoll Separating Solution; Biochrom) den-
sity gradient centrifugation and enriched for CD34+ cells as described previ-
ously (Giebel et al., 2004). Cells were cultured in a humidified atmosphere at
37C and 5%CO2 at a density of 0.5–13 10
5 cells/ml in IMDM (Lonza) supple-
mented with 20% FBS (Biochrom), 100 U/ml penicillin, and 100 U/ml strepto-
mycin (Life Technologies) and with FLT3L, SCF, and TPO each at 10 ng/ml final
concentration (all PeproTech).
Flow Cytometric Analyses and Cell Sorting
Antibodies used for FACS analysis and sorting are listed in Table S2. For ana-
lyses of human graft compositions in mouse BM, sample cells were stained
with antibodies against CD34, CD133, CD45, CD38, CD19, CD20, CD4,
CD13, CD14, and CD15. Prior to staining, Fc receptors were blocked using pu-
rified rat anti-mouse CD16/CD32 monoclonal antibodies (BD). Mice with more
than 0.1% positive human CD45 cells in the BM were considered to be
engrafted.
For bulk analyses of CFC assay-derived cells via flow cytometry, we har-
vested all colonies of given cultures. Briefly, the colony containing methylcel-
lulose was diluted with 1ml PBS and dispended by gentle pipetting. Cells were
then washed twice in a total volume of 15 ml PBS. Next, unspecific binding
sites were blocked, and cells were stained for flow cytometric analyses.
Flow cytometric analyses were performed on a FC500 flow cytometer
(Beckman Coulter), a LSRII (BD), and a FACSAria I (BD). Dead cells were
excluded by propidium iodide or DAPI staining. Flow Count Beads (Beckman
Coulter) were used for quantification purposes. Cells were sorted using a
FACSAria I cell sorter. The sort purity was routinely assessed by recovery of
sorted cells and was >99.5%.
In Vitro Differentiation Assays
Primitivemyeloid/lymphoid hematopoietic progenitors were assessed as LTC-
ICs/NK-ICs as described previously (Giebel et al., 2006). For CFC assays, 100–
400 sorted cells were seeded into 1 ml MethoCult H4434 (StemCell Technol-
ogies). Hematopoietic colonies were scored after 12–14 days. For secondary
CFC assays, all cells harvested from individual colonies were dissociated and
seeded into 1 ml MethoCult.
To test for their erythroid differentiation potential, CD34+ cells were cultured
in a two-phase liquid culture system in limiting dilutions in 96-well plates. Cells
were initially raised in DMEM supplemented with 15% FBS, 1% BSA (BSA;
Roth), 0.1 M b-mercaptoethanol (Life Technologies), 0.128 mg/ml human
iron-saturated transferrin (R&D Systems), 1 U/ml EPO, 292 mg/ml L-glutamine,
100 U/ml penicillin, and 100 U/ml streptomycin (Life Technologies). In the first
phase (days 1–7), the culture medium was supplemented with 10 ng/ml rhSCF
and 40 ng/ml rhIGF-1. From day 8 to 14, the medium was supplemented with
1 mg/ml insulin. Half of themediumwas changed every 3–4 days. After 2weeks,
the cells were analyzed and quantified by flow cytometry.1550 Cell Reports 3, 1539–1552, May 30, 2013 ª2013 The AuthorsTo test for their MK differentiation potential, CD34+ cells were cultured in a
limiting dilution in 96-well plates. They were raised in IMDMsupplementedwith
5% BSA, 0.1 M b-mercaptoethanol, 0.2 mg/ml human iron-saturated trans-
ferrin, 1 mg/ml insulin (Sigma), 50 ng/ml TPO, 10 ng/ml IL-3 (PeproTech),
10 ng/ml IL-6 (PeproTech), 100 U/ml penicillin, and 100 U/ml streptomycin.
Half-media changes were performed on a weekly basis. Obtained cells were
analyzed and quantified by flow cytometry 2 weeks postseeding.
Lympho-myeloid potentials were tested in the clonal MS-5 assay as
described previously by Doulatov et al. (2010). Briefly, single-sorted hemato-
poietic progenitors were deposited onto monolayers of stromal MS-5 cells in
96-well plates. They were raised in H5100 medium (StemCell Technologies)
supplemented with SCF (100 ng/ml), IL-7 (20 ng/ml), TPO (50 ng/ml), and
IL-2 (10 ng/ml; all PeproTech). Cocultures were maintained for 4 weeks with
weekly half-media changes before cells were harvested by physical dissocia-
tion, filtered, and stained with antibodies against CD45, CD15, CD14, CD56,
and CD19. Myeloid cells were identified as CD15+/CD14+ and CD19CD56
cells and lymphoid as CD56+/CD19+ and CD14CD15 cells. Wells with
both myeloid and lymphoid cells were scored as lympho-myeloid.
Mouse Repopulation Assay
NOD/LtSz-Prkdcscid/Prkdcscid (NOD/SCID) and NOD.Cg-PrkdcscidIl2rg
tm1Wjl/SzJ (NSG)mice were bred and housed at the University Hospital Essen
animal care facility. Animal experiments were performed in accordance with
institutional guidelines approved by the Animal Care Committee of the Univer-
sity Hospital Essen. Eight to 14-week-old mice were sublethally irradiated
(3.25 Gy) 24 hr before transplantation. Following sort purification, cells were
immediately transplanted intravenously (tail vein) using a 29G needle
(Micro -Fine+; BD). Unless indicated otherwise, transplanted mice were
sacrificed after 8 weeks. Marrow was isolated by flushing of bone cavities
(femur and tibia) with 5 ml IMDM. The cells obtained were stained and sorted
as described under ‘‘Flow Cytometric Analyses and Cell Sorting.’’
Statistics
Experimental results from independent experiments are reported as SD of the
mean unless indicated otherwise. Significance analyses and data assembly
were performed with the paired, two-sided Student’s t test using Microsoft
Excel and GraphPad Prism. Limiting-dilution analyses were calculated with
the LDA-Stat/L-Calc-Software (StemCell Technologies).
For additional details on the materials and methods used herein, please see
the Extended Experimental Procedures.
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